Last updated: 2026-09-06 12:35:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tango Therapeutics, Inc. (TNGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $22,53, with a market capitalization of $3,80B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6,25 to $34,39. This page covers its latest market performance, valuation, price trends and company information.
$3,80B | |
$22,48 | |
$34,39 | |
$1,03 | |
$22,76 | |
1,25M | |
3,68M | |
-- | |
$34,39 | |
$6,25 | |
-- | |
-- |
Tango Therapeutics, Inc. (TNGX) last closed at $22,76 as of 2026-09-04 23:32:00, unchanged from the previous close of $22,76.
During the latest regular trading session, TNGX traded between $1,03 and $34,39, with a volume of 1,25M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Tango Therapeutics, Inc. (TNGX) moved from $25,28 to $22,53, representing a decline of 10,88% ($2,75).
The stock traded between $21,64 and $26,85 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,74 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 57,9%
TNGX is currently trading at $22,53, placing it 57,9% of the way from its 52-week low of $6,25 to its 52-week high of $34,39. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 137 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tango Therapeutics, Inc. (TNGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.